Age: 44.0
Sex: F
Vaccine: RAB
Symptoms: Nasal disorder, Pruritus
Clinical narrative: Initial report received on 26 November 2007 from a facility. The reporter's name was not provided. A 44-year-old female patient, with history of allergy to Sulfa, CT dyes, BIAXIN, and NIACIN, had received a third dose of a six dose series of IMOVAX Rabies vaccine (lot number Z0943-1), in the right deltoid on 02 June 2007. Three days later, on 05 June 2007, the patient experienced slight malaise and fatigue. Treatments received, and diagnostic tests performed were not provided. Per the reporter, the patient had extreme anxiety regarding administration of the rabies vaccinations that resulted in her calling the clinic several times a day. The recovery status of the patient was not provided. The patient's rabies immunization flow sheet was provided. The patient subsequently received three more doses of IMOVAX Rabies vaccine; the fourth dose was administered on 09 June 2007 (lot number A0017-2) intramuscularly in the left deltoid; the fifth dose was administered on 23 June 2007 (lot number A0017-2) intramuscularly in the right deltoid; and the sixth dose was administered on 21 September 2007 (lot number A0259-2) intramuscularly in the right deltoid. Follow-up received on 12 February 2008 via telephone contact to a health care professional that clarified all the previously received information. Per the reporter, the patient was exposed to a bat, sometime prior to 26 May 2007. As a result, she received a first dose of IMOGAM Rabies HT (lot number A0373-4, expiration date 26 April 2009) with one ,milliliter infiltrated into the wound, and 6.9 milliliters administered intramuscularly in the left and right gluteal area on 26 May 2007. She also received a five dose series of IMOVAX. The first dose of IMOVAX (lot number Z0877-2, expiration date 10 March 2008) was received intramuscular in the right deltoid on 26 May 2007. The second dose of IMOVAX (lot number reported as Z0877, Sanofi Pasteur SAP lot number Z0877-2) was administered intramuscular in the left deltoid on 29 May 2007. The third dose of IMOVAX (lot number Z0943-1, expiration date 03 October 2008) was administered intramuscular in the right deltoid on 02 June 2007. The fourth, dose of IMOVAX (lot number A0017-2, expiration date 01 March 2009) was administered intramuscular in the left deltoid on 09 June 2007. The fifth dose of IMOVAX (lot number A0017-2, expiration date 01 March 2009) was administered intramuscular in the right deltoid on 23 June 2007. After review of the case, on 02 June 2007, when the patient had received the third dose of IMOVAX it was noted on the immunization record that the patient had taken ZYRTEC the same day for slight nasal itching. The onset date of the slight nasal itching was not reported. Three days later, on 05 June 2007, the patient experienced slight malaise and fatigue. The patient did not receive any treatments. Recovery status is unknown. The patient completed the last two doses of the five dose series of IMOVAX without any incidence. The patient experienced a second exposure to a bat sometime prior to 18 September 2007, and was administered two booster doses of IMOVAX. The first booster dose was administered on 18 September 2007 and the second booster dose was administered on 21 September 2007. At an unspecified amount of time after the second booster dose on 21 September 2007, the patient experienced eye irritation and gum sensitivity that is reported in case 2007-03434.